ASX Top Gainers Today (10 December 2025): Lion Rock Minerals, Tissue Repair and Silver Stocks Light Up the Australian Market

The Australian share market is treading water at index level today, but under the surface it’s a very different story. As of mid‑afternoon on 10 December 2025, the S&P/ASX 200 is roughly flat, yet pockets of small‑cap miners, healthcare names and a handful of financials are posting double‑digit percentage gains. ^[1]

Driving much of the action: record‑high silver prices, renewed enthusiasm for critical minerals, and a cluster of stock‑specific catalysts ranging from exploration results to earnings upgrades. ^[2]

Below is a rundown of the biggest stock gainers on the ASX today, based on Market Index’s “Top Gainers (percentage) today” scan (price > A$0.01), together with the latest news, forecasts and analysis available on 10 December 2025.

Market snapshot: quiet index, noisy leaderboard

ASX 200: Around flat by early afternoon, with materials and energy stocks outperforming, while technology and interest‑rate‑sensitive names lag. ^[3]
Macro backdrop: Investors are positioning ahead of the US Federal Reserve’s final 2025 meeting this week, with the market debating whether Chair Jerome Powell will hint at further rate cuts after an already volatile year for bonds. ^[4]
Commodities: Silver has surged to an all‑time high near US$60 per ounce, almost doubling in 2025 amid supply shortages and strong industrial demand. Copper has also hit record levels, fueling a broad rally in resource equities. ^[5]

That combination – flat headline index plus explosive moves in commodities and speculative growth names – is exactly the kind of environment that produces a “noisy” top‑gainers list.

Biggest ASX percentage gainers today (intraday)

According to Market Index, these are the top 10 percentage gainers on the ASX as of around 2:15pm AEDT on Wednesday, 10 December 2025:

Lion Rock Minerals (ASX: LRM) – up 41.7% to A$0.034 , turnover ~A$815k. One-year performance: +401% . Basic materials (critical minerals).
Tissue Repair (ASX: TRP) – up 31.3% to A$0.42 , A$209k in value traded. One-year performance: +62% . Healthcare/biotech.
Alvo Minerals (ASX: ALV) – up 22.6% to A$0.065 , A$295k traded. One-year performance: –18% . Copper‑zinc explorer in Brazil.
Powerhouse Ventures (ASX: PVL) – up 20.8% to A$0.145 , thin turnover around A$52k. One-year performance: +101% . Small financial services/VC style investor.
H&G High Conviction (ASX: HCF) – up 20.0% to A$0.018 on almost no volume, still down ~98% over 12 months. Listed investment company.
Latrobe Magnesium (ASX: LMG) – up 20.0% to A$0.024 , A$166k traded. One‑year performance: –3% , despite today’s jump. Critical minerals/industrial.
Audeara (ASX: AUA) – up 19.1% to A$0.05 , A$26k in turnover. One-year performance: +14% . Hearing‑health technology.
Platina Resources (ASX: PGM) – up 17.2% to A$0.034 , A$39k traded. One-year performance: +70% . Base and precious metals explorer.
Albion Resources (ASX: ALB) – up 16.4% to A$0.064 , with modest volume. One-year performance: +39% . Early‑stage explorer.
Investigator Silver (ASX: IVR) – up 16.2% to A$0.079 , on ~A$1.26m of turnover. One-year performance: +93% . Silver developer.

Beyond the top 10, the leaderboard is dominated by resources and silver names such as Unico Silver (USL, +12.7%) , Sun Silver (SS1, +9.1%) , Boab Metals (BML, +9.1%) , Silver Mines (SVL, +6.6%) and Kingsgate Consolidated (KCN, +6.5%) . High‑beta names like DroneShield (DRO, +8.5%) , 4DMedical (4DX, +7.5%) , Lumos Diagnostics (LDX, +7.6%) , Larvotto Resources (LRV, +7.6%) , Bell Financial Group (BFG, +7.2%) , EDU Holdings (EDU, +7.2%) and Immutep (IMM, +7.0%) are also featuring prominently.

Let’s look at the key stories behind some of today’s biggest moves.

Lion Rock Minerals (LRM): critical minerals tie‑up supercharges the share price

Move today: +41.7% (intraday)
1‑year performance: +400%

Lion Rock Minerals’ surge is directly linked to news that its strategic partner, Tronox , has received conditional, non-binding letters of support from Export Finance Australia and the US Export–Import Bank for up to US$600 million in potential financing.

Tronox recently acquired a 5% cornerstone stake in Lion Rock , and the two are aligned on developing the Minta Rutile and Monazite Project in Cameroon , a potential new source of rare‑earth‑rich monazite and high‑grade rutile.

According to Proactive, the proposed funding is aimed at building a new rare earth supply chain – including mine extensions, infrastructure and processing facilities – that would support Western critical‑minerals strategies. ^[6]

Why the market cares

The financing support, while still conditional, strengthens Tronox’s ability to back long‑term project development , which investors see as indirectly de‑risking Lion Rock.
Lion Rock plans to use proceeds from its own placement to accelerate drilling, resource definition and metallurgical testwork at Minta, which could crystallize value from what is still an early‑stage exploration story.

Risk lens: Lion Rock remains a small, high-risk explorer . Visual sampling and early studies are promising, but there is no guarantee Minta ultimately becomes a producing asset. A lot of today’s move reflects sentiment around geopolitical critical‑minerals themes rather than cash‑flow visibility.

Tissue Repair (TRP): wound‑healing gel keeps the biotech on traders’ radar

Move today: +31.3%
1‑year performance: +61.5%

Tissue Repair is a clinical‑stage biopharmaceutical company best known for TR Pro+ , a topical wound‑healing gel that received Therapeutic Goods Administration (TGA) approval as an Australian‑listed medicine in mid‑2024. ^[7]

That TGA green light enabled broader domestic distribution of TR Pro+ in multiple pack sizes, and the company has been working on commercial rollout and pipeline development since. ^[8]

There has been no major price‑sensitive announcement on the ASX today , so the 30%+ jump appears to reflect:

Renewed speculative interest in small‑cap healthcare , a pocket of the market that had been under pressure earlier in the year. ^[9]
Traders revisiting stories with existing regulatory approvals but relatively modest market capitalizations (TRP is ~A$25m).

Looking ahead: The investment case hinges on evidence of sustained sales traction for TR Pro+ , progress in any prescription‑grade formulations, and the company’s ability to secure distribution beyond Australia. Until then, the share price is likely to remain volatile and highly news‑driven.

Alvo Minerals (ALV): copper‑zinc discovery excitement at Touro

Move today: +22.6%
1‑year performance: –17.7%

Alvo Minerals has been rewarded for a strong exploration update at its Touro Prospect in Brazil, where all five diamond drill holes completed so far have intersected massive and semi-massive copper and zinc sulphides across roughly 750 meters of strike . ^[10]

Key points from recent coverage of the discovery:

A 100% “hit rate” for sulphide mineralization in the first five holes.
Shallow mineralization along a 750m confirmed strike, with deeper conductive targets still untested.
Visual estimates in standout holes suggest significant chalcopyrite and sphalerite content, with assays expected in the coming weeks.

Why it matters

Touro sits within Alvo’s broader Palma VMS district , already host to a JORC‑compliant 7.6Mt resource at 2.0% copper‑equivalent across multiple deposits. A new discovery approaching the scale of existing deposits could materially expand the project’s economic potential.

Caveat: Today’s buying is based on visual mineralization and early‑stage interpretations. Final grades, continuity and metallurgy will ultimately determine value – and those answers are still months away.

Latrobe Magnesium (LMG): critical minerals theme plus US backing

Move today: +20.0%
1‑year performance: –3.3%

Latrobe Magnesium is developing a world‑first magnesium production plant in Victoria’s Latrobe Valley, using patented technology to convert power‑station fly ash into magnesium metal and a suite of by‑products such as supplementary cementitious material and silica. ^[11]

Latrobe has been in focus since October, when the US Export–Import Bank (EXIM) indicated it was prepared to finance up to US$122 million for Stage 2 of the company’s commercial magnesium plant, as part of a wider US–Australia critical‑minerals partnership worth more than US$2.2 billion in potential support. ^[12]

Today’s rally likely reflects:

Ongoing enthusiasm for critical minerals linked to US supply‑chain government security , particularly where‑backed debt funding could reduce project‑finance risk. ^[13]
Renewed local media coverage highlighting US backing for Latrobe and other strategic miners. ^[14]

From a risk perspective, Latrobe remains in the project-execution phase . The demonstration plant is still ramping up, and the economics of a larger‑scale operation will depend on capex, operating costs and magnesium prices over the next decade.

Audeara (AUA): trading update lifts a hearing‑health minnow

Move today: +19.1%
1‑year performance: +13.6%

Audeara is a niche hearing‑health company that sells headphones and TV listening devices tailored using a proprietary hearing‑profile algorithm . ^[15]

On 8 December, the company released a December trading update , flagged by the ASX as price‑sensitive, which detailed improved sales momentum heading into the key holiday period and progress in its audiology and retail channels. ^[16]

Today’s follow‑through buying appears to be:

Momentum‑driven , as traders respond to better‑than‑feared sales numbers from a previously overlooked micro‑cap;
Supported by the broader bid into small‑cap healthcare and tech seen across the market today. ^[17]

However, Audeara’s market cap is under A$10m , liquidity is thin, and the path to scale remains challenging. Small position sizing and a long time horizon are typically essential in this part of the market.

Silver and precious‑metals plays: Investigator, Andean, Unico, Silver Mines & Kingsgate

Record silver prices are the clear macro driver behind a cluster of today’s gainers. Australian silver producers have broadly outperformed the underlying silver price over the past month , with investors positioning for ongoing supply deficits and industrial demand from solar, EVs and electronics. ^[18]

Investigator Silver (IVR)

Investigator Silver, developer of the Paris silver project in South Australia , is up about 16% today on heavy turnover, taking its 12‑month gain to nearly 93%.

The company has been continuously advancing feasibility and enabling work; today’s move looks largely driven by:

Macro tailwinds from the silver price spike;
Its status as a relatively advanced ASX silver name with meaningful leverage to higher prices. ^[19]

Andean Silver (ASX: ASL)

Although just outside the top 10 by percentage, Andean Silver is one of the most closely watched movers, up almost 15% to A$2.15 following an A$30m institutional placement at A$1.85 per share and an associated share purchase plan. ^[20]

Funds are being used to accelerate resource conversion and exploration at the Cerro Bayo silver-gold project in Chile , where the company has been reporting “bonanza” grade drill results and expanding its resource base through 2025. ^[21]

A recent valuation piece noted that despite the capital raise, Andean Silver’s share price is now trading almost 50% below consensus analyst targets , highlighting both perceived upside and the usual dilution/execution risks common to capital-intensive explorers. ^[22]

Silver Mines (SVL) & technical forecasts

Silver Mines (ASX: SVL) , which aims to build Australia’s pre‑eminent silver company in New South Wales, is up around 6.6% today, adding to a roughly 118% gain over the past 12 months. ^[23]

A popular technical-analysis service currently classifies Silver Mines as a “hold/accumulate” candidate after a strong two-week run, projecting modest upside over the next three months but flagging high day-to-day volatility and mixed short-term signals. ^[24]

As always, such model‑driven forecasts are not guarantees ; they’re best seen as one input among many for traders who actively use technical signals.

Healthcare & medtech winners: 4DMedical, Lumos and Immutep

4DMedical (4DX)

Move today: +7.5% to A$2.15; 1‑year performance: +343%

4DMedical continues its remarkable run as investors focus on:

Growing US adoption of its lung-imaging software;
A recent strategic partnership with Philips , which has raised questions about how far earnings can scale and whether the current valuation already bakes in a lot of success. ^[25]

Recent analysis has highlighted both the recurring‑revenue potential of the platform and valuation debate after the stock’s multi‑bagger move in 2025. ^[26]

Lumos Diagnostics (LDX)

Move today: +7.6%; 1‑year performance: +595%

Lumos Diagnostics, which develops and manufactures rapid diagnostic tests, has staged a dramatic share‑price recovery from its 2023 lows following restructuring, recapitalization and new commercial agreements.

Today’s gain appears to track broader risk‑on sentiment in small‑cap diagnostics , but after such a steep 12‑month rally, the stock is highly sensitive to any setbacks in regulatory or commercial milestones.

Immutep (IMM)

Move today: +7.0%
1‑year performance: roughly flat

Immutep is back in the spotlight thanks to a major global licensing and collaboration agreement for its lead immunotherapy candidate eftilagimod alfa (efti) , signed with a large pharmaceutical partner. ^[27]

The deal:

Extends efti’s reach into multiple international markets while preserving Immutep’s rights in key territories such as North America, Europe, Japan and Greater China. ^[28]
Leaves manufacturing control with Immutep, which could translate into stronger strategic leverage if pivotal trials succeed. ^[29]

Analysts see the structure as a validation of efti’s potential , but the company remains a clinical-stage biotech , with all the binary trial and regulatory risks that imply.

Bell Financial Group (BFG) and EDU Holdings (EDU): fundamental re‑rates

Bell Financial Group (BFG)

Move today: +7.2% to A$1.26

In contrast to many speculative names on the list, Bell Financial Group is rising on hard numbers . Market Index’s live blog notes that Bell’s shares jumped as much as 10% in early trade after the broker reported unaudited profit before tax of A$48.2m for the first 11 months of 2025 , up around 17% year-on-year and a sharp turnaround from a weak first half. ^[30]

The update suggests:

A stronger second half for retail and institutional broking volumes;
Resilience in margin lending and wealth‑management income despite rate volatility. ^[31]

For yield‑oriented investors, Bell Financial is often assessed on its dividend capacity and leverage to equity‑market activity , rather than explosive growth – making today’s presence on the top‑gainers list relatively rare.

EDU Holdings (EDU)

Move today: +7.2% to A$0.965
1‑year performance: about +972% ^[32]

EDU Holdings, owner of tertiary‑education businesses such as Australian Learning Group and Ikon Institute, has quietly become one of the ASX’s top performers in 2025 . ^[33]

Key recent catalysts include:

A FY25 guidance upgrade and announcement of a selective buy‑back initiative on 1 December; ^[34]
A subsequent “becoming a substantial holder” notice lodged on 9 December, signaling fresh institutional interest. ^[35]

Together, those moves have reinforced a fundamental re‑rating narrative : positive earnings momentum, capital management that can enhance per‑share metrics, and growing recognition from professional investors. At the same time, after almost a ten‑bagger in a year , any disappointment could trigger sharp pullbacks.

DroneShield (DRO): sharp intraday rebound after governance storm

Move today: +8.5% to A$2.11
1‑year performance: +232% ^[36]

Counter‑drone technology specialist DroneShield has been one of the ASX’s most talked‑about stocks in 2025 – first for its spectacular rise, then for a brutal November sell‑off driven by insider selling and governance concerns .

Recent coverage shows:

The stock had surged as much as 800% by early October off the back of contract wins and strong earnings. ^[37]
In November, DroneShield’s market value dropped by roughly 75% after the CEO and other directors sold tens of millions of dollars’ worth of shares, a key US contract announcement had to be withdrawn, and the US CEO resigned. ^[38]
The company has since responded to ASX price‑query letters , stating there is no undisclosed price‑sensitive information and that recent trading reflects directors’ share disposals. It has also committed to an independent review of its disclosure and trading policies. ^[39]

From a technical-analysis perspective, one widely used quant model currently labels DroneShield a “sell candidate” , noting that while a short-term “pivot bottom” has formed and the stock bounced about 13% from late-November lows, the broader trend remains down with a wide 3-month projected trading range. ^[40]

Today’s 8%+ move looks like a combination of short‑covering and speculative bargain‑hunting rather than a clean fundamental reset. With valuation still rich relative to historical revenue and major governance questions unresolved, this remains one of the most volatile stories on the ASX.

Key themes from today’s ASX top gainers

Across all of today’s big movers, several themes stand out:

Silver and precious metals in the spotlight
- Record silver prices and supply‑deficit narratives are driving outsized moves in Andean Silver, Investigator, Unico Silver, Silver Mines, Sun Silver, West Coast Silver, Boab Metals and Kingsgate . ^[41]
Critical minerals and base‑metal discoveries
- Latrobe Magnesium, Alvo Minerals, Larvotto Resources and others are benefiting from the US–Australia push to build non-China supply chains and from genuinely strong exploration updates. ^[42]
Small‑cap healthcare & medtech resurgence
- Tissue Repair, 4DMedical, Lumos Diagnostics, Immutep and several tiny names such as Inhalerx and Renerve are riding a mini‑rotation back into higher‑risk growth after a tough period for biotech. ^[43]
Fundamental upgrades still matter
- Moves in Bell Financial Group and EDU Holdings show that earnings upgrades, buy-backs and strong guidance can still command attention in a day otherwise dominated by micro-cap speculation. ^[44]
Volatility cuts both ways
- Some of today’s biggest winners – especially in resources and micro‑cap healthcare – have also been among the market’s biggest losers on prior down days. High intraday percentage moves are often a function of thin liquidity and leveraged sentiment , not necessarily new fundamental information.

What this means for investors and traders

For active traders and investors scanning Google News or Discover for “ASX top gainers today” or “biggest stock movers on the Australian share market” , today’s tape offers a few practical takeaways:

Check the catalyst : Is the move driven by hard news (drilling results, earnings, guidance, major contracts) or just a sector-wide macro theme and low volume? Today you can see both types clearly.
Know your time frame : Stories like Lion Rock, Alvo, Andean Silver and Latrobe Magnesium are fundamentally multi‑year critical‑minerals plays, but the share prices can move 20–40% in a single day on feeling alone.
Use external forecasts cautiously : Technical models that classify stocks as “hold”, “buy” or “sell candidates” (like those applied to Silver Mines or DroneShield ) can be helpful for timing, but they are not investment advice and often change quickly as price action evolves. ^[45]
Diversify exposure to high‑risk names : Micro‑caps such as Audeara, Tissue Repair and some of the smaller explorers are inherently risky. Many professional investors limit them to a small slice of a diversified portfolio.

References